Editas Medicine, Inc.
$2.63
Stock Quotes & Analysis
EDIT3.66%
$2.63
Latest AAPL News (Need to figure out how to make this dynamic)
test
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Editas Medicine, Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: EDIT
Exchange: NMS
Employees: 246
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
 | 11 Hurley Street, Cambridge, MA, United States |
 | 617 401 9000 |
 | https://www.editasmedicine.com |